Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.-Reference-Cited by-同舟云学术

Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:9001-9001
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Atkins Michael B.¹,Kudchadkar Ragini Reiney²,Sznol Mario³,McDermott David F.⁴,Lotem Michal⁵,Schachter Jacob⁶,Wolchok Jedd D.⁷,Urba Walter John⁸,Kuzel Timothy⁹,Schuchter Lynn Mara¹⁰,Slingluff Craig L.¹¹,Ernstoff Marc S.¹²,Fay Joseph W.¹³,Friedlander Philip Adam¹⁴,Gajewski Thomas¹⁵,Zarour Hassane M.¹⁶,Rotem-Yehudar Rinat¹⁷,Sosman Jeffrey Alan¹⁸

Affiliation:

1. Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

2. University of South Florida, H. Lee Moffitt Cancer Center, Tampa, FL

3. Yale University, New Haven, CT

4. Beth Israel Deaconess Medical Center, Boston, MA

5. Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

6. Ella Institute for Research and Treatment of Melanoma, Sheba Medical Center, Affiliated to Sackler Faculty of Medicine Tel Aviv University, Ramat-Gan, Israel

7. Memorial Sloan Kettering Cancer Center, New York, NY

8. Earle A. Chiles Research Institute and Providence Cancer Center, Portland, OR

9. Feinberg School of Medicine, Northwestern University, Chicago, IL

10. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

11. University of Virginia School of Medicine, Charlottesville, VA

12. Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, NH

13. Baylor Medical Center, Dallas, TX

14. Mount Sinai Medical Center, Ruttenberg Cancer Clinic, New York, NY

15. The University of Chicago, Chicago, IL

16. University of Pittsburgh Cancer Institute, Pittsburgh, PA

17. CureTech Ltd, Yavne, Israel

18. Vanderbilt University Medical Center, Nashville, TN